The ISN and the Mario Negri Institute for Pharmacological Research are pleased to announce the first of two webinars “New insights into clinical management of complement-mediated thrombotic microangiopathies”, supporting the theme of the ISN Frontiers Meeting “Complement-related kidney diseases: Classification, genetics and treatment” that will take place in Bergamo, June 23-25 2022. The term thrombotic microangiopathies (TMA) define a group of conditions characterized by nonimmune thrombocytopenia and microangiopathic hemolytic anemia with varying degrees of organ damage. Complement activation has been definitely implicated in the etiology of atypical hemolytic uremic syndrome (aHUS) and C5-inhibition dramatically improved clinical outcome. Increasing evidence also support a variable role of complement in other forms of TMA.

1) the identification of patients with complement-mediated TMA, and the impact of genetic and biochemical characterization;

2) the optimal dose, the duration of treatment and the monitoring of the C5-inhibitors eculizumab and ravulizumab;

3) the clinical perspectives of other emerging complement inhibitors.